Scarica l'app Stockscreener
17.93
3.30%
-0.517
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$18.45
Aprire:
$18.19
Volume 24 ore:
1.32M
Relative Volume:
0.34
Capitalizzazione di mercato:
$13.27B
Reddito:
$220.00K
Utile/perdita netta:
$-746.08M
Rapporto P/E:
-17.80
EPS:
-1.0074
Flusso di cassa netto:
$-211.81M
1 W Prestazione:
-5.65%
1M Prestazione:
-19.96%
6M Prestazione:
-26.55%
1 anno Prestazione:
-15.44%
Intervallo 1D:
$17.55
$18.30
Intervallo di 1 settimana:
$17.37
$19.18
Portata 52W:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Confronta SMMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.87 | 13.73B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.20 | 105.61B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
647.23 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.79 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.87 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.40 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
What MACD and RSI say about Summit Therapeutics Inc.2025 Technical Overview & Real-Time Stock Movement Alerts - newser.com
Summit Therapeutics Says Ivonescimab, Chemotherapy Combination Shows Benefit in Treating Lung Cancer - MarketScreener
Summit Therapeutics Reports Positive Phase III Trial Results - TipRanks
Summit Therapeutics Inc Reports Positive Phase III Trial Results - TradingView
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China - Markets Financial Content
Is Summit Therapeutics Inc. building a consolidation baseJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
What institutional flow reveals about Summit Therapeutics Inc.2025 Top Gainers & Technical Confirmation Trade Alerts - newser.com
Is Summit Therapeutics Inc. showing signs of accumulationJuly 2025 Price Swings & Weekly Hot Stock Watchlists - newser.com
Should you hold or exit Summit Therapeutics Inc. nowJuly 2025 Gainers & Free Reliable Trade Execution Plans - newser.com
Will Summit Therapeutics Inc. stock outperform growth indexesSwing Trade & Verified Short-Term Trading Plans - fcp.pa.gov.br
Applying sector rotation models to Summit Therapeutics Inc.Weekly Profit Analysis & AI Powered Market Entry Strategies - newser.com
Transforming Lung Cancer Care Through Targeted Science and Patient-First InnovationSummit Therapeutics - Oncodaily
Is Summit Therapeutics Inc. stock reversal real or fakeShare Buyback & Daily Oversold Bounce Ideas - newser.com
Analyzing Summit Therapeutics Inc. with risk reward ratio chartsJuly 2025 Recap & Capital Protection Trade Alerts - newser.com
Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire
Summit Therapeutics (SMMT) Is Down 6.4% After $513M Shelf Filing and Ivonescimab Clinical Updates—Has The Bull Case Changed? - Yahoo Finance
News impact scoring models applied to Summit Therapeutics Inc.Trade Signal Summary & Daily Technical Forecast Reports - newser.com
A Look at Summit Therapeutics (SMMT) Valuation Following Positive HARMONi Trial Results and Regulatory Progress - Yahoo Finance
Can Summit Therapeutics Inc. hit a new high this monthJuly 2025 Trends & Community Consensus Picks - newser.com
1 Monster Stock in the Making to Buy and Hold - AOL.com
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Insiders Are Snapping Up These 2 Stocks — and Analysts Like What They See - Yahoo Finance
Summit (NASDAQ: SMMT) at SITC 2025: HARMONi-A; first Phase III OS benefit for ivonescimab - Stock Titan
Summit Therapeutics (SMMT) Aims for FDA Nod for Ivonescimab in N - GuruFocus
Jefferies Cuts Summit Therapeutics (SMMT) Price Target, Keeps Buy Rating - Insider Monkey
Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025 - Insider Monkey
Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent
13 Stocks to Buy with Exponential Growth Heading into 2026 - Insider Monkey
10 Stocks Under $20 to Buy According to Analysts - Insider Monkey
Summit Therapeutics (SMMT) files for 26.68M share offering by selling stockholders - StreetInsider
Why Wall Street Is Backing These 3 Comeback Stocks - Investing.com
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Summit Therapeutics Inc Azioni (SMMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
5.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):